Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Hsieh on Unmet Needs of Rare Kidney Cancer Variants

October 4th 2019

James J. Hsieh, MD, PhD, discusses unmet needs in non-clear cell renal cell carcinoma.

Dr. Pal on CRISPR-Based Technology in RCC

October 4th 2019

Sumanta Kumar Pal, MD, discusses potential developments with vaccines and CRISPR/Cas9 technology coming down the pipeline in renal cell carcinoma.

Dr. Bhatt on Identification of Immune Checkpoint Pathway in RCC

October 2nd 2019

Rupal S. Bhatt, MD, PhD, discusses the discovery of HHLA2/KIR3DL3, a novel therapeutic immune checkpoint pathway in renal cell carcinoma.

Uzzo Shares Insight on Sequencing Surgery in RCC

October 2nd 2019

Robert G. Uzzo, MD, MBA, FACS, discusses the evolving yet relevant role of surgery in renal cell carcinoma.

Dr. Uzzo on the Evolving Role of Surgery in Metastatic Kidney Cancer

October 1st 2019

Robert G. Uzzo, MD, MBA, FACS, discusses the evolving role of surgery in metastatic kidney cancer.

Atezolizumab/Chemo Improves PFS in Metastatic Urothelial Cancer

September 30th 2019

The first-line combination of atezolizumab (Tecentriq) and chemotherapy led to an improvement in median progression-free survival compared with placebo/chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

ESMO 2019: Dr. Bekaii-Saab Highlights Important Trials in GI Malignancies

September 29th 2019

ESMO 2019: Dr. Mirza on Important Trials with PARP Inhibitors in Ovarian Cancer

September 29th 2019

ESMO 2019: Dr. McGregor Highlights Impactful 2019 Prostate Cancer Studies

September 29th 2019

ESMO 2019: Dr. Spigel Highlights Progress in Lung Cancer

September 29th 2019

ESMO 2019: Dr. Rugo Highlights Progress in Breast Cancer

September 29th 2019

ESMO 2019: Dr. O'Shaughnessy Highlights Progress in Breast Cancer

September 29th 2019

ESMO 2019: Dr. Choueiri Discusses Novel Treatment Strategies in GU Cancers

September 29th 2019

ESMO 2019: Dr. Hamid Discusses Exciting Immunotherapy Data in Melanoma

September 29th 2019

ESMO 2019: Dr. Ramalingam Discusses Confirmatory Data in Advanced NSCLC

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 3

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 2

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 1

September 29th 2019

Enfortumab Vedotin Plus Pembrolizumab Shows Promise in Urothelial Cancer

September 28th 2019

More than 70% of patients with cisplatin-ineligible locally advanced urothelial cancer had objective responses to the investigational antibody-drug conjugate enfortumab vedotin plus pembrolizumab (Keytruda).

Sacituzumab Govitecan Active in Heavily Pretreated Metastatic Urothelial Cancer

September 28th 2019

Sacituzumab govitecan demonstrated clinical activity with an overall response rate of 29% in patients with heavily pretreated metastatic urothelial carcinoma.